Joachim von Pawel

TL;DR: CV had an increased efficacy compared with E in an unselected population of elderly patients with advanced NSCLC, and more skin toxicity and diarrhea was seen with E compared to more myelotoxicity, neurotoxicity and constipation with CV.

TL;DR: Daily metronomic NVBo therapy in extensively pretreated patients with advanced NSCLC is feasible and safe at the recommended dose of 30 mg/d, and blood concentrations were consistent with anti-angiogenic or immune modulating pharmacologic properties of vinorelbine.

TL;DR: Although the performance of serum TK for diagnosis and therapy monitoring of advanced lung cancer was poor, it has a promising prognostic relevance which will have to be further validated.

TL;DR: Treatment of pleural MM with pemetrexed alone or in combination with platinum was safe and active as first and second-line therapy and efficacy outcomes were better for chemonaïve than for pretreated patients, and P was less hematotoxic than PC or PCb.

TL;DR: The observed survival times of above 18 and 15 months, respectively, since occurrence of cranial disease manifestation in line with the achieved progression-free survival times by the erlotinib third-line therapy are remarkable.